MBI assessed as supplementary screening tool for women with dense breasts.
Molecular breast imaging (MBI) is effective as a supplementary screening tool to mammography for women with dense breasts, according to a study published in the American Journal of Roentgenology.
Researchers from Ohio, California, and New Hampshire performed a retrospective study to assess the utility of MBI as a supplementary screening tool for 1,696 women with dense breast tissue. They sought to determine cancer detection rates, recall rates, biopsy rates, and positive predictive values (PPVs).
The results showed that 13 mammographically occult malignancies were detected among the study group. Eleven were invasive, one was node positive, and one had unknown node positivity. Other findings showed:
• Lesion size ranged from 0.6 to 2.4 cm, mean 1.1 cm[[{"type":"media","view_mode":"media_crop","fid":"50915","attributes":{"alt":"©RSNA 2015.","class":"media-image media-image-right","id":"media_crop_9213433233653","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"6242","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 151px; width: 170px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"©RSNA 2015.","typeof":"foaf:Image"}}]]
• Incremental cancer detection rate was 7.7%
• Recall rate was 8.4%
• Biopsy rate was 3.7%
• PPV for recall (PPV 1) was 9.1%
• PPV for biopsy (PPV 3) was 19.4%
While MBI does expose women to a higher radiation dose than does standard mammography, the effective dose from the MBI exam was 2.3 mSv, compared with a typical mammography dose of 0.56 mSv. “When incorporated into a community-based clinical practice environment, molecular breast imaging yielded a high incremental cancer detection rate of 7.7 percent at an acceptable radiation dose,” the researchers concluded.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.